Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.39 |
| ▸ | RXRA | P19793 | 8/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27245066 | 0.91 | OTUD7B (0.43) | OTUD7BNR1H2RXRANR1H3MAPK1 | |
| SCHEMBL30992215 | 0.89 | OTUD7B (0.42) | OTUD7BNR1H2RXRANR1H3MAPK1 | |
| SCHEMBL30890482 | 0.85 | POLB (0.40) | NR1H2RXRANR1H3MAPK1KDM1A | |
| SCHEMBL27245166 | 0.84 | OTUD7B (0.48) | OTUD7B | |
| SCHEMBL30890510 | 0.83 | OTUD7B (0.40) | OTUD7BMAPK1 | |
| SCHEMBL30992278 | 0.82 | NR1H2 (0.40) | OTUD7BNR1H2RXRANR1H3MAPK1 | |
| SCHEMBL30992236 | 0.82 | NR1H2 (0.40) | OTUD7BNR1H2RXRANR1H3MAPK1 | |
| SCHEMBL30890380 | 0.81 | OTUD7B (0.35) | OTUD7B | |
| SCHEMBL30890622 | 0.80 | NR1H2 (0.38) | NR1H2RXRANR1H3EPHX2 | |
| SCHEMBL30992272 | 0.80 | NR1H2 (0.43) | NR1H2RXRANR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | OTUD7B 2426/4885NR1H2 449/4885RXRA 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.